The COVID-19 pandemic accelerated a change that was already underway with regards to the digitisation of biopharma marketing – and the increasing ubiquity of omnichannel.
As the landscape of healthcare changes, so too must the way that we interpret and measure performance and success. This is particularly evident in marketing.
A multichannel marketing approach, together with compelling content, is the ultimate way for pharma to deliver the message in the right way to its customers.
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.